Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma

Clinical Lymphoma

Volumn 3, Issue 2, 2002, Pages 111-116

  Emmanouilides, Christos ^a   Lill, Michael ^b   Telatar, Milhan ^a   Rosenfelt, Fred ^b   Grody, Wayne ^a   Territo, Mary ^a   Rosen, Peter ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Anti CD20 antibody; bcl 2 translocation; Molecular remission; Polymerase chain reaction; Stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MITOXANTRONE; PROTEIN BCL 2; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER RECURRENCE; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 18; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE REARRANGEMENT; HUMAN; IN VIVO STUDY; LEUKAPHERESIS; MALE; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; SIDE EFFECT; STEM CELL TRANSPLANTATION;

EID: 0036754602     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2002.n.017     Document Type: Article

References (33)

1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995; 333:1540-1545.
2. Pettengell R. Autologous stem cell transplantation in follicular non-Hodgkin’s lymphoma. Bone Marrow Transplant 2002; 29(suppl 1): S1-S4.
3. Cao TM, Horning S, Negrin RS, et al. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Biol Blood Marrow Transplant 2001; 7:294-301.
4. Apostolidis J, Foran JM, Johnson PW, et al. Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 1999; 17:216-221.
5. Gisselbrecht C, Bosly A, Lepage E, et al. Autologous hematopoietic stem cell transplantation in intermediate and high grade non-Hodgkin’s lymphoma: a review. Ann Oncol 1993; 4(suppl 1):7-13.
6. McCann JC, Kanteti R, Shilepsky B, et al. High degree of occult tumor contamination in bone marrow and peripheral blood stem cells of patients undergoing autologous transplantation for non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant 1996; 2:37-43.
7. Jacquy C, Lambert F, Soree A, et al. Peripheral blood stem cell contamination in mantle cell non-Hodgkin lymphoma: the case for purging? Bone Marrow Transplant 1999; 23:681-686.
8. + cells and lymphoma cells in non-Hodgkin’s lymphoma patients mobilized with different growth factors. J Hematother Stem Cell Res 2001; 10:167-176.
9. Negrin RS, Kiem HF, Schmidt-Wolf IG, et al. Use of the polymerase chain reaction to monitor the effectiveness of ex vivo tumor cell purging. Blood 1991; 77:654-660.
10. Stewart AK, Vescio R, Schiller G, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001; 19:3771-3779.
11. Freedman AS, Gribben JG, Neuberg D, et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88:2780-2786.
12. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 1997; 90:2188-2195.
13. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-445.
14. Foran JM, Gupta RK, Cunningham D, et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 2000; 109:81-88.
15. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-2833.
16. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosis. Clin Cancer Res 2001; 7:709-723.
17. Alas S, Bonavida B, Emmanouilides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin’s lymphoma by pentoxifylline and rituximab. Anti-cancer Res 2000; 20:2961-2966.
18. Emmanouilides C, Rosen P, Telatar M, et al. Excellent tolerance of rituximab when given after mitoxantrone/cyclophosphamide: an effective and safe combination for indolent non-Hodgkin’s lymphoma. Clin Lymphoma 2000; 1:146-151; discussion 152-143.
19. Colombat F, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97:101-106.
20. Zinzani PL, Bendandi M, Gamberi B, et al. Complete molecular remission induced by rituximab in a patient with diffuse large cell lymphoma. Haematologica 2000; 85:437-438.
21. Hardingham JE, Kotasek D, Sage RE, et al. Molecular detection of residual lymphoma cells in peripheral blood stem cell harvests and following autologous transplantation. Bone Marrow Transplant 1993; 11:15-20.
22. Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325:1525-1533.
23. Williams CD, Goldstone AH, Pearce RM, et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin’s lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 1996; 14:2454-2464.
24. Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al. The clinical significance of molecular response in indolent follicular lymphomas. Blood 1998; 91:2955-2960.
25. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-242.
26. Buckstein R, Imrie K, Spaner D, et al. Stem cell function and engraftment is not affected by “in vivo purging” with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin’s lymphoma. Semin Oncol 1999; 26:115-122.
27. Lazzarino M, Arcaini L, Bernasconi P, et al. A sequence of immunochemotherapy with rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 2002; 116:229-235.
28. Flinn IW, O’Donnell PV, Goodrich A, et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant 2000; 6:628-632.
29. Schmitz N. Rituximab in autologous stem cell transplantation for follicular lymphoma. Anticancer Drugs 2001; 12 (suppl 2): S21-S24.
30. Voso MT, Pantel G, Weis M, et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin’s lymphoma. Br J Haematol 2000; 109:729-735.
31. Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96:864-869.
32. Ha CS, Cabanillas F, Lee MS, et al. Serial determination of the bcl-2 gene in the bone marrow and peripheral blood after central lymphatic irradiation for stages I-III follicular lymphoma: a preliminary report. Clin Cancer Res 1997; 3:215-219.
33. Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94:3325-3333.